Rapt Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by Lifesci Capital

Lifesci Capital upgraded shares of Rapt Therapeutics (NASDAQ:RAPT - Free Report) to a strong-buy rating in a research report report published on Tuesday, Marketbeat.com reports. They currently have $31.00 price target on the stock. Lifesci Capital also issued estimates for Rapt Therapeutics' Q2 2025 earnings at ($0.67) EPS, Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.59) EPS.

Other analysts have also recently issued research reports about the stock. HC Wainwright raised their target price on shares of Rapt Therapeutics to $27.00 and gave the stock a "buy" rating in a research note on Thursday, July 10th. UBS Group dropped their target price on shares of Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Finally, Wall Street Zen downgraded shares of Rapt Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 21st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $21.67.

Rapt Therapeutics Trading Up 5.2%

RAPT traded up $0.66 during trading hours on Tuesday, hitting $13.31. 66,312 shares of the company's stock were exchanged, compared to its average volume of 130,058. Rapt Therapeutics has a 12-month low of $5.67 and a 12-month high of $27.84. The firm has a 50 day moving average of $8.88 and a 200 day moving average of $8.74. The firm has a market cap of $220.15 million, a P/E ratio of -0.69 and a beta of -0.09.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of ($2.48) by $1.84. As a group, research analysts expect that Rapt Therapeutics will post -2.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Rapt Therapeutics

A number of hedge funds have recently added to or reduced their stakes in RAPT. Checkpoint Capital L.P. bought a new stake in shares of Rapt Therapeutics in the first quarter valued at approximately $134,000. AQR Capital Management LLC bought a new stake in shares of Rapt Therapeutics in the first quarter valued at approximately $188,000. ADAR1 Capital Management LLC lifted its position in Rapt Therapeutics by 408.4% in the first quarter. ADAR1 Capital Management LLC now owns 5,970,768 shares of the company's stock worth $7,284,000 after purchasing an additional 4,796,455 shares during the period. Nantahala Capital Management LLC lifted its position in Rapt Therapeutics by 303.1% in the first quarter. Nantahala Capital Management LLC now owns 5,012,927 shares of the company's stock worth $6,116,000 after purchasing an additional 3,769,414 shares during the period. Finally, Comerica Bank lifted its position in Rapt Therapeutics by 53.9% in the first quarter. Comerica Bank now owns 89,327 shares of the company's stock worth $109,000 after purchasing an additional 31,287 shares during the period. Institutional investors and hedge funds own 99.09% of the company's stock.

About Rapt Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.